Fly News Breaks for March 12, 2015
UTHR
Mar 12, 2015 | 08:00 EDT
As previously reported, Argus upgraded United Therapeutics to Buy from Neutral. The firm believes United Therapeutics is entering a new phase of growth following the recent approval of Unituxin in the treatment of neuroblastoma. Argus said the new product offers a diversified revenue stream and recommends buying shares. Price target is $195.
News For UTHR From the Last 2 Days
There are no results for your query UTHR